Principles in the biomodulation of cytotoxic drugs by interferons

Scott Wadler, Edward L. Schwartz

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The interferons (IFNs) were identified as novel, endogenous antiviral agents in 1957. Shortly thereafter, antiproliferative and immunostimulatory activities were identified for these compounds. Based on these observations, partially purified IFNs entered clinical trials in the 1970s and recombinant IFNs in 1980. IFNs have demonstrated important clinical activity in hairy cell leukemia, melanoma, renal cell carcinoma, and Kaposi's sarcoma as monotherapy. Shortly after their introduction into clinical trials, however, preclinical studies demonstrated synergistic interactions between IFNs and cytotoxic drugs. Numerous preclinical trials have demonstrated a broad spectrum of interactions between IFNs and at least 20 cytotoxic agents both in vitro and in vivo. Early clinical trials suggest a benefit to combinations of fluorouracil and recombinant interferon alfa in refractory gastrointestinal malignancies. Combinations of IFNs and cytotoxic agents deserve further investigations; however, different principles apply for combining IFNs with cytotoxic drugs than for the design of combination chemotherapy regimens.

Original languageEnglish (US)
Pages (from-to)45-48
Number of pages4
JournalSeminars in Oncology
Volume19
Issue number2 SUPPL. 3
StatePublished - 1992

Fingerprint

Interferons
Pharmaceutical Preparations
Cytotoxins
Clinical Trials
Hairy Cell Leukemia
Kaposi's Sarcoma
Drug Design
Drug Combinations
Combination Drug Therapy
Renal Cell Carcinoma
Interferon-alpha
Fluorouracil
Antiviral Agents
Melanoma
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Principles in the biomodulation of cytotoxic drugs by interferons. / Wadler, Scott; Schwartz, Edward L.

In: Seminars in Oncology, Vol. 19, No. 2 SUPPL. 3, 1992, p. 45-48.

Research output: Contribution to journalArticle

@article{0f80e2ff16ae4dbdbb2e26c5e6bcedf7,
title = "Principles in the biomodulation of cytotoxic drugs by interferons",
abstract = "The interferons (IFNs) were identified as novel, endogenous antiviral agents in 1957. Shortly thereafter, antiproliferative and immunostimulatory activities were identified for these compounds. Based on these observations, partially purified IFNs entered clinical trials in the 1970s and recombinant IFNs in 1980. IFNs have demonstrated important clinical activity in hairy cell leukemia, melanoma, renal cell carcinoma, and Kaposi's sarcoma as monotherapy. Shortly after their introduction into clinical trials, however, preclinical studies demonstrated synergistic interactions between IFNs and cytotoxic drugs. Numerous preclinical trials have demonstrated a broad spectrum of interactions between IFNs and at least 20 cytotoxic agents both in vitro and in vivo. Early clinical trials suggest a benefit to combinations of fluorouracil and recombinant interferon alfa in refractory gastrointestinal malignancies. Combinations of IFNs and cytotoxic agents deserve further investigations; however, different principles apply for combining IFNs with cytotoxic drugs than for the design of combination chemotherapy regimens.",
author = "Scott Wadler and Schwartz, {Edward L.}",
year = "1992",
language = "English (US)",
volume = "19",
pages = "45--48",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 3",

}

TY - JOUR

T1 - Principles in the biomodulation of cytotoxic drugs by interferons

AU - Wadler, Scott

AU - Schwartz, Edward L.

PY - 1992

Y1 - 1992

N2 - The interferons (IFNs) were identified as novel, endogenous antiviral agents in 1957. Shortly thereafter, antiproliferative and immunostimulatory activities were identified for these compounds. Based on these observations, partially purified IFNs entered clinical trials in the 1970s and recombinant IFNs in 1980. IFNs have demonstrated important clinical activity in hairy cell leukemia, melanoma, renal cell carcinoma, and Kaposi's sarcoma as monotherapy. Shortly after their introduction into clinical trials, however, preclinical studies demonstrated synergistic interactions between IFNs and cytotoxic drugs. Numerous preclinical trials have demonstrated a broad spectrum of interactions between IFNs and at least 20 cytotoxic agents both in vitro and in vivo. Early clinical trials suggest a benefit to combinations of fluorouracil and recombinant interferon alfa in refractory gastrointestinal malignancies. Combinations of IFNs and cytotoxic agents deserve further investigations; however, different principles apply for combining IFNs with cytotoxic drugs than for the design of combination chemotherapy regimens.

AB - The interferons (IFNs) were identified as novel, endogenous antiviral agents in 1957. Shortly thereafter, antiproliferative and immunostimulatory activities were identified for these compounds. Based on these observations, partially purified IFNs entered clinical trials in the 1970s and recombinant IFNs in 1980. IFNs have demonstrated important clinical activity in hairy cell leukemia, melanoma, renal cell carcinoma, and Kaposi's sarcoma as monotherapy. Shortly after their introduction into clinical trials, however, preclinical studies demonstrated synergistic interactions between IFNs and cytotoxic drugs. Numerous preclinical trials have demonstrated a broad spectrum of interactions between IFNs and at least 20 cytotoxic agents both in vitro and in vivo. Early clinical trials suggest a benefit to combinations of fluorouracil and recombinant interferon alfa in refractory gastrointestinal malignancies. Combinations of IFNs and cytotoxic agents deserve further investigations; however, different principles apply for combining IFNs with cytotoxic drugs than for the design of combination chemotherapy regimens.

UR - http://www.scopus.com/inward/record.url?scp=0026557955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026557955&partnerID=8YFLogxK

M3 - Article

C2 - 1373005

AN - SCOPUS:0026557955

VL - 19

SP - 45

EP - 48

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2 SUPPL. 3

ER -